Biomarker Discovery and the VOC Atlas – Julia Greenwood at BBCon 2024

Volatile Biomarker Discovery and the VOC Atlas

00:00 Introduction

00:18 Presentation ‘Volatile Biomarker Discovery and the VOC Atlas’

14:55 Question and answer session

Talk Abstract:

Volatile organic compounds (VOCs) can arise from underlying metabolism and are detectable in exhaled breath, therefore offering a promising route to non-invasive diagnostics. Owlstone Medical has undertaken a large project to build a VOC Atlas as a reference database of chemically confirmed VOC identities that are genuinely breath-borne. This will facilitate future breath biomarker discovery and subsequent biomarker validation in clinical studies and can be used to facilitate cross-study data comparisons for improved standardization in the field of breath research. Building the VOC Atlas requires precise, accurate, and robust workflows for quantification and chemical identification. The atlas project is also being expanded and made public with support from key collaborative partners such as the FDA, Gates Foundations, and FDA to provide the highest-quality resource to support breath as a biomarker platform for clinical and research use. 

 

Speaker Biography:

Julia joined Owlstone in July 2018 as a product development lead, and is currently the VP of Programme – Research Products and Services. She is responsible for our product strategy as well as managing our delivery teams. Julia has come from a background in product development: her previous roles include Principal Physicist at Cambridge Consultants where she worked on a wide range of technologies for consumer and industrial applications. Her primary focus was on sensing technologies and optical physics. Julia studied Physics at the university of Bristol and went on to do research in Surgical Robotics and Medical Imaging at Imperial College London.

 

The Breath Biopsy Conference 2025 is scheduled for 4th and 5th November. Click the button to express interest in the next Breath Biopsy Conference:

 

EXPRESS INTEREST